New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
15:09 EDTTMK, LEG, APC, HIG, EW, YUM, LIFE, GILDCompanies reporting After the Market Close on Monday, February 4
Notable companies reporting after the bell include Anadarko Petroleum (APC), Gilead Sciences (GILD), Edwards Lifesciences (EW), Leggett & Platt (LEG), Life Technologies (LIFE), The Hartford Financial Services Group (HIG), Torchmark (TMK) and Yum! Brands (YUM).
News For APC;GILD;EW;LEG;LIFE;HIG;TMK;YUM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 27, 2015
16:11 EDTHIGHartford Financial raises quarterly dividend to 21c from 18c per share
The board of directors also declared a quarterly dividend of 21c per share of common stock, payable on Oct. 1 to shareholders of record at the close of business on Sept. 1. This represents an increase of 3c per share, or 17%, over the prior quarterly dividend.
16:10 EDTHIGHartford Financial raises share repurchase plan by $1.6B
The Hartford announced that its board of directors approved an increase in and extension of the company’s capital management plan. The current equity repurchase plan was increased by $1.6B and extended through Dec. 31, 2016. The debt management plan was expanded to include the repayment of $275M of debt maturing in 2016 and extended through Dec. 31, 2016.
16:09 EDTHIGHartford Financial reports Q2 core EPS 91c, consensus 77c
Reports Q2 revenue $4.685B, consensus $4.7B. Book value per diluted share, excluding accumulated other comprehensive income, was $42.41, up 8% over June 30, 2014.
15:03 EDTHIGNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Baidu (BIDU), consensus $10.58... Avalonbay Communities (AVB), consensus $1.92... Hartford Financial (HIG), consensus 77c... Southwestern Energy (SWN), consensus 6c... PartnerRe (PRE), consensus $2.35... Allison Transmission (ALSN), consensus 34c... Swift Transportation (SWFT), consensus 37c.
13:46 EDTHIGHartford Financial technical notes ahead of earnings
The stock has been in a stable bullish uptrend since the lows of August in 2012. Of late the bullish price channel has begun to steepen, implying greater upside momentum into earnings. If the news is bullish, resistance levels to watch as potential upside objectives would be at $47.42, $49.14, and $50.47. If the news is a bearish surprise, the first important support would be the 30-day moving average at $44. On a breakdown below that average, next supports to watch as potential downside objectives would be at $42.98, $41.75, and $40.63.
11:57 EDTGILDStocks with call strike movement; FB GILD
Subscribe for More Information
08:42 EDTGILDGilead July weekly volatility increases into Q2 and outlook
Subscribe for More Information
05:56 EDTGILDStocks with implied volatility movement; CRM GILD
Subscribe for More Information
July 24, 2015
06:27 EDTGILDGilead price target raised to $131 from $120 at Piper Jaffray
Subscribe for More Information
July 23, 2015
12:45 EDTGILDGilead July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
July 22, 2015
06:29 EDTAPCAnadarko coverage assumed with an Outperform at Credit Suisse
Subscribe for More Information
July 21, 2015
14:12 EDTGILDGilead reports study of E/C/F/TAF met primary endpoint
Gilead Sciences announced detailed 48-week data from an open-label Phase 3 study evaluating its investigational once-daily single tablet regimen of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg, or E/C/F/TAF, among 1,436 virologically suppressed adult patients switching from tenofovir disoproxil fumarate-containing regimens. The study met its primary endpoint by demonstrating non-inferiority of E/C/F/TAF to the TDF-based regimens at Week 48. The study also demonstrated statistical superiority among patients with HIV-1 RNA levels less than 50 copies/mL at Week 48 and statistically significant improvements in bone and renal laboratory parameters. These data were presented in an oral session at the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention in Vancouver, Canada. Among the 1,436 patients who were randomized in the study, virologic success rates at Week 48 were higher in patients taking E/C/F/TAF, 97% versus 93% for all TDF-based regimens; difference in percentages: 4.1%, 95% CI: 1.6% to 6.7%. The rates of virologic failure were similar between the two arms, with E/C/F/TAF, 1.0% and TDF-based regimen, 1.3%. General safety was similar between the two arms through 48 weeks of treatment, with similar percentages of patients in each group having any adverse events. Adverse events leading to treatment discontinuation were more common among patients treated with a TDF-based regimen.
10:24 EDTYUMOptions with decreasing implied volatility
Subscribe for More Information
July 20, 2015
10:13 EDTYUMOptions with decreasing implied volatility
Subscribe for More Information
09:16 EDTHIGThe Hartford names Morris Tooker Chief Underwriting Officer
The Hartford has named A. Morris “Mo” Tooker as EVP and chief underwriting officer for the company’s property and casualty businesses, effective July 21. Tooker will report to Doug Elliot, president of The Hartford. Tooker will oversee underwriting across The Hartford’s Small Commercial, Middle Market, Large Commercial and Personal Lines segments. He will lead development of the company’s underwriting approach for new markets and growth areas.
07:33 EDTGILDInternational AIDS Society to hold a conference
Subscribe for More Information
07:32 EDTLIFEaTyr Pharma announces transitions in clinical developments
Subscribe for More Information
July 17, 2015
10:21 EDTGILDCigna says 98.4% of customers treated with hep C drug Harvoni are cured
Subscribe for More Information
10:04 EDTYUMYum! Brands mentioned cautiously by Seeking Alpha contributor
Subscribe for More Information
09:03 EDTGILDGilead granted orphan status for gastric cancer treatment
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use